IART · Integra LifeSciences Holdings Corporation · Stock research

Current Thesis

The binary this name was carrying is behind it. Integra printed Q2 on 2026-07-29: adjusted EPS $0.56 against a $0.48 consensus, revenue $418.761M against $418.647M — a clean EPS beat on an in-line top line. Underneath, organic revenue was flat year over year (Q2 call commentary), a step down from the +1.3% organic reported at the 2026-05-05 Q1 print. Q3 guidance brackets rather than beats: adjusted EPS $0.53–$0.61 versus $0.56 consensus, sales $410M–$425M versus $418.1M consensus.

The tape has responded by giving back the leg. The last completed daily close was $17.25 on 2026-08-07, 13.1% below the $19.85 52-week high, with RSI(14) at 40.7 — while the three-month return is still +23.9%. The distressed-to-fair re-rating that defined this name from the $8.70 low is now fully expressed in sell-side marks, and those marks arrived in a cluster: Citi Neutral $19 (2026-07-08), BMO Market Perform $19 (2026-07-09), UBS initiating Neutral $19 (2026-07-28), Wells Fargo Equal Weight raised to $18 (2026-07-30). Argus's Buy $25 from 2026-06-18 remains the lone rating meaningfully above the group. Benzinga's aggregation as of 2026-08-08 shows 3 buy / 7 hold / 2 sell.

Life-cycle label: SATURATED. What dates it is the 22-day run of mainstream initiations and target moves (2026-07-08 through 2026-07-30) all landing Hold-grade at $18–$19, arriving after a +23.9% three-month move, followed by an EPS beat on 2026-07-29 that the stock did not hold. The coverage is now complete and the incremental buyer it produced is Neutral-rated.

Bullish and bearish views on Integra LifeSciences Holdings Corporation

The model's bull view on Integra LifeSciences Holdings Corporation (IART), in brief: Q2 2026 (2026-07-29): adjusted EPS $0.56 vs $0.48 consensus, above the company's own guidance range, with revenue $418.761M vs $415.61M a year earlier (+0.8% reported). The bear view: Two consecutive quarters of no demand growth: organic +1.3% at Q1 (2026-05-05), flat at Q2 (2026-07-29). Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-29): adjusted EPS $0.56 vs $0.48 consensus, above the company's own guidance range, with revenue $418.761M vs $415.61M a year earlier (+0.8% reported).
• GAAP profitability returned: net income $4.48M in Q2 2026 against a net loss of $484.07M in the year-ago quarter, which laps the impairment that made trailing GAAP EPS meaningless.
• Margin direction: operating margin 9.6% in Q2 versus 7.9% a year earlier; adjusted EBITDA margin 18.7% (Q2 call coverage, 2026-07-29).
• The EPS guide held while revenue was trimmed: FY26 adjusted EPS reaffirmed at $2.40–$2.50 on 2026-07-29, with the revenue reduction attributed to FX rather than unit demand — a distinction that matters if the dollar reverses.
• Supply normalization becoming revenue: management guided a controlled SurgiMend relaunch in Q4 2026 on the 2026-07-29 call, following the "improved supply reliability" framing that Argus credited in its 2026-06-18 upgrade.
• Coverage floor keeps rising: Wells Fargo lifted its target to $18 on 2026-07-30 from $15; the old $16 / $15 / $12 cluster from earlier in 2026 is gone.

Bear Case

• Two consecutive quarters of no demand growth: organic +1.3% at Q1 (2026-05-05), flat at Q2 (2026-07-29). The earnings line is doing all the work.
• FY26 revenue guidance was cut, from $1.662B–$1.702B to $1.654B–$1.695B (2026-07-29), landing the range below the $1.676B consensus mid.
• Q3 guidance offers no raise: adjusted EPS $0.53–$0.61 straddles the $0.56 consensus and the sales range midpoint sits under the $418.1M consensus.
• Beat composition is policy-linked again: the CFO attributed Q2 adjusted-EPS outperformance to operational execution and favourable tariff dynamics, offsetting higher interest expense. The same IEEPA tariff benefit flagged at Q1 is still inside the number.
• Tissue Technologies was flat on difficult year-ago comparisons and reimbursement pressure (Q2 call, 2026-07-29) — the segment carrying the regenerative-supply recovery story.
• Every new rating is a Hold at fair value. Four sell-side actions between 2026-07-08 and 2026-07-30 all landed $18–$19 with Neutral/Market Perform/Equal Weight ratings. The gap from $17.25 to those marks is desks calling fair value there, and there is no fresh Buy-rated cluster underwriting a higher number.

Setup & Price Structure

• Last completed daily close $17.25 (2026-08-07); 52-week high $19.85; distance from high −13.1%; RSI(14) 40.7; three-month return +23.9%.
• The June structure was a shelf built above the ~$17.43 area and the old $17.83 high. At $17.25 price has already slipped under that shelf on a daily basis. The weekly frame is what has not yet confirmed.
• Post-print behaviour is the cleanest read available: an EPS beat printed 2026-07-29 and by 2026-08-07 the stock sits below where the pre-print Hold-grade coverage was struck. Beats that do not hold a bid describe a buyer set that is already filled.
• RSI(14) at 40.7 with no breakdown yet puts price in the middle of the range — the momentum that produced the +23.9% quarter has drained without the structure formally failing.
• Crowding and positioning observables (not verdicts): four sell-side marks inside 22 days after the move; a ratings distribution of 3 buy / 7 hold / 2 sell per Benzinga as of 2026-08-08; no earnings date inside the next 30 days now that the Q2 binary has resolved; a lone above-market target ($25, Argus, 2026-06-18) that is nearly two months old and has not been matched by a second desk.

Catalyst Calendar (next 30 days)

• No company-dated event falls inside 2026-08-08 → 2026-09-07 in the sources reviewed. The Q2 print (2026-07-29) was the binary and it has come and gone.
• ~2026-10-28 (est.) — Q3 2026 results. Cadence basis: Q1 on 2026-05-05, Q2 on 2026-07-29. This is the next date that can move organic growth off flat.
• Ongoing, undated — any 8-K on manufacturing, recall or compliance. This is the one item that does not wait for a calendar.

Elapsed catalysts

• Q4 2026 (no fixed date, guided 2026-07-29) — controlled SurgiMend relaunch. The first revenue evidence that the manufacturing remediation converts to sales. (passed 11d ago)

What Would Change Our Mind

The structure at risk is the June post-Argus shelf near $17.43, which price has already lost on a daily basis; the leg is confirmed failed on a weekly close below $17. That level is roughly 1.5% under the 2026-08-07 close of $17.25, so the condition is live rather than theoretical.

Separately, the read breaks on evidence rather than tape in three ways. A renewed manufacturing, recall or compliance 8-K resets the turnaround premise regardless of price — the original collapse to $8.70 came from exactly that channel. A Q3 print (~2026-10-28 est.) that shows organic growth still flat or negative alongside a further FY revenue trim would confirm that the cost-out and tariff-driven EPS line is standing on a business that is not growing.

The reverse case: organic growth re-accelerating above the +1.3% Q1 rate with an FY revenue raise, or a second desk joining Argus above $22 with a Buy, would argue the leg was a pause and not a top. Absent one of those, the coverage arriving Hold-grade at $18–$19 through late July is the ceiling the market is trading against.

Correlation Notes

• Idiosyncratic, not thematic. No medtech peer cluster (GMED / NUVA / SYK) moved with the June–July leg; this is execution-specific and does not receive sector confirmation on the way up or down.
• A weaker dollar mechanically re-widens the guide; a stronger one pressures it again at Q3.
• US trade policy sits inside the EPS line. The IEEPA tariff dynamic was cited as a driver of adjusted-EPS outperformance at both Q1 and Q2. A change in that regime hits the earnings guide directly, not just the top line.
• Reimbursement policy drives Tissue Technologies. Flat segment revenue at Q2 was attributed partly to reimbursement pressure, which links this segment to CMS policy rather than to hospital procedure volumes.
• Interest expense is a headwind. The CFO cited higher interest expense being offset at Q2 — a leveraged balance sheet keeps this name rate-sensitive on the earnings line.